Febuxostat ameliorates methotrexate-induced lung damage

Area of Science:

• Pulmonary toxicology
• Pharmacology
• Inflammation research

Background:

• Methotrexate (MTX) overdose can cause significant lung damage.
• Understanding the mechanisms of MTX-induced lung injury is crucial.
• Investigating potential protective agents like febuxostat is warranted.

Purpose of the Study:

• To assess lung structural damage from MTX overdose.
• To investigate the mechanisms of MTX-induced lung injury, including oxidative stress, apoptosis, and inflammation.
• To evaluate the protective role of febuxostat against MTX-induced lung toxicity.

Main Methods:

• Rats were divided into control, MTX-treated, and febuxostat-treated groups.
• Lung tissues were analyzed histologically and immunohistochemically for inflammatory markers (iNOS, COX-2).
• Oxidative stress markers, apoptosis, and inflammatory mediators (NF-kB, TNF-a, IL-1) were quantified.

Main Results:

• MTX overdose led to lung inflammation, fibrosis, apoptosis, increased oxidative stress (MDA, GSH, SOD), and elevated inflammatory markers (NF-kB, IL-1, TNF-a, iNOS, COX-2).
• Febuxostat treatment preserved lung architecture, reduced fibrosis, and mitigated oxidative stress and inflammation.
• Febuxostat normalized iNOS and COX-2 levels, while NF-kB, IL-1, and TNF-a showed partial reduction.

Conclusions:

• MTX overdose causes lung injury through oxidative stress, apoptosis, and sterile inflammation, leading to fibrosis.
• Febuxostat demonstrates significant lung-protective effects against MTX-induced toxicity.
• Febuxostat's protective mechanisms involve anti-inflammatory and antioxidant actions, preserving lung structure.